Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.

Moshe Talpaz, MD, discusses best practices in monitoring patients with CML and applying multidisciplinary care.

Daniel DeAngelo, MD, PhD, provides his perspective on improving CML care through dose adjustment or treatment discontinuation.

An overview of the general toxicities patients may experience while undergoing therapy for chronic myeloid leukemia.

A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.

Experts share their personal experience with asciminib as later-line therapy for patients with chronic myeloid leukemia.

Shared insight on asciminib’s role in chronic myeloid leukemia in light of available clinical data.

Jorge Cortes, MD, breaks down third-line treatment options for patients who progress with chronic myeloid leukemia.

A brief review of the inherent challenges in guiding patients through several lines of therapy for chronic myeloid leukemia.

Considerations for selecting optimal second-line therapy for chronic myeloid leukemia when a patient progresses.

Daniel DeAngelo, MD, PhD, highlights the role that tyrosine kinase inhibitors play in the CML treatment paradigm.

Key opinion leader perspectives on assessing a patient’s response to therapy for chronic myeloid leukemia.

Shared insight on chromosomal abnormalities and genetic alterations that influence the disease course and management of CML.

Expert overview of chronic myeloid leukemia, including considerations for the unmet needs in management as they exist today.

The panel of experts discuss the clinical differences between well-differentiated systemic mastocytosis and chronic mast cell leukemia.

The panel of experts in SM discuss the diagnosis and treatment of a 68-year-old female with mast cell leukemia.

Dan DeAngelo, MD, PhD, presents the case of a patient with indolent systemic mastocytosis and urticaria pigmentosa.

A panel of experts share their reactions to the approval of avapritinib and discuss the clinical implications.

Dan DeAngelo, MD, PhD, reviews key efficacy data from the phase II PATHFINDER study.

Patricia Lugar, MD, MS, shares an allergist’s perspective regarding treatment algorithms and supportive care recommendations for patients with systemic mastocytosis.

The panel of experts in SM discuss the diagnosis and management of a 46-year-old woman with systemic mastocytosis.

Dan DeAngelo, MD, PhD, presents the case of a 46-year-old woman with systemic mastocytosis and associated gastrointestinal symptoms.

Patricia Lugar, MD, MS, shares treatment algorithm and supportive care recommendations for a 75-year-old man with systemic mastocytosis.

The panel of experts in SM discuss the diagnosis and management of a 75-year-old man with systemic mastocytosis.

Dan DeAngelo, MD, PhD, presents the case of a 75-year-old man with systemic mastocytosis and reviews WHO diagnostic criteria.

Prithviraj Bose, MD, and Patricia Lugar, MD, MS, discuss the considerations and testing options for hereditary alpha tryptasemia in patients with systemic mastocytosis.

The panel of experts highlights the importance of assessing symptomology and clinical characteristics in mast cell disorders.

Experts in the field of mast cell disorders discuss the epidemiology and diagnostic criteria of systemic mastocytosis.